Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT5LS6T)

• DTT Name: Aurora kinase B (AURKB) DTT Info
• Gene Name: AURKB

Molecule-Related Drug & Molecule List

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT9283	DMQ94CT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
ABT-348	DMMZOYN	Haematological malignancy	2B33.Y	Phase 2	[2]
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[3]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
AMG 900	DMASGXJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
AZD-1152-HQPA	DMMW72C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
BI-811283	DMNUY32	Acute myeloid leukaemia	2A60	Phase 1	[7]
BI-831266	DMOJZUE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
BI-847325	DMY4B6J	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
CYC116	DMUMHXT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
GSK1070916	DMXRPT6	Advanced solid tumour	2A00-2F9Z	Phase 1	[11]
GSK1070916A	DMCJUI9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
HPP-607	DM5VSZR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
MK-5108	DMFGYKS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
R763	DME0CJ9	Haematological malignancy	2B33.Y	Phase 1	[14]
SNS-314	DMAC5F2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
TAK-901	DM5KDGI	Haematological malignancy	2B33.Y	Phase 1	[16]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-03814735	DMO4S6T	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[3]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deguelin	DMXT7WG	Esophageal squamous cell carcinoma	2E60.1	Investigative	[17]

References

• [1] A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
• [2] Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
• [3] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [4] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [5] Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
• [6] Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80.
• [7] Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32.
• [8] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22.
• [9] doi: 10.1158/1535-7163.TARG-13-B281
• [10] Clinical pipeline report, company report or official report of Cyclacel.
• [11] Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
• [13] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [14] Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.
• [15] SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
• [16] Clinical pipeline report, company report or official report of Takeda (2009).
• [17] An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H- Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407.